US Patent 12077593 Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
Patent 12077593 was granted and assigned to Regeneron Pharmaceuticals on September, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+30 properties)
Article (+466 characters)
US Patent 12077593 Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
Article
Patent abstract
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Daniel B. Dix0
Douglas Kamen0
Kenneth S. Graham0
Scott M. Walsh0
Date of Patent
September 3, 2024
0Patent Application Number
172258870
Date Filed
April 8, 2021
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 12077593 Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
